中国现代医学杂志2025，Vol.35Issue(21)：30-35,6.DOI:10.3969/j.issn.1005-8982.2025.21.005
脂多糖与非酒精性脂肪性肝病治疗
Lipopolysaccharide and nonalcoholic fatty liver disease treatment
摘要
Abstract
Non-alcoholic fatty liver disease(NAFLD)has emerged as one of the most prevalent hepatic disorders in China and the world.Currently,NAFLD is on the rise globally and represents the most significant and prevalent cause of chronic liver cirrhosis,imposing a substantial medical burden worldwide.There are still no effective treatments available for NAFLD.In recent years,numerous studies on drug treatment for NAFLD has been undertaken,which focuses on protecting liver injury by intervening in major signaling pathways related to lipopolysaccharide(LPS),including farnesoid X receptor,Toll-like receptor 4 and nuclear factor-kappa Additionally,therapeutic effects are also achieved by modulating gut microbiota composition,restoring intestinal barrier integrity,and suppressing the activation of LPS-induced inflammatory cells and associated mediators,ultimately achieving therapeutic effects against NAFLD.This article comprehensively reviews the latest advancements in targeting LPS for NAFLD treatment,aiming to provide evidence-based references for clinical management of NAFLD.关键词
非酒精性脂肪性肝病/脂多糖/治疗措施Key words
nonalcoholic fatty liver disease/lipopolysaccharides/treatment分类
临床医学引用本文复制引用
徐雨鹏,刘小微,熊思妍,李佳豪,徐雨轩,黄锦,洪芬芳,杨树龙..脂多糖与非酒精性脂肪性肝病治疗[J].中国现代医学杂志,2025,35(21):30-35,6.基金项目
国家自然科学基金(No:82360880,No:82060661) （No:82360880,No:82060661）
江西省自然科学基金(No:20232ACB206057,No:20212BAB206092) （No:20232ACB206057,No:20212BAB206092）
江西省教育厅科技研究重点项目(No:GJJ218104) （No:GJJ218104）
江西省高等学校教学改革研究课题(No:JXJG-22-130-1) （No:JXJG-22-130-1）
